AngeloFoca Thursday, 09/12/19 01:52:30 AM Re: pgsd post# 243664 Post # of 244450 https://xconomy.com/national/2019/01/16/merck-and-the-future-of-immuno-oncology-a-chat-with-roger-perlmutter/2/ Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter Jan 16, 2019 X: Where do you see cancer care going in the near-term? Roger Perlmutter: You’re not going to see much monotherapy anymore, except perhaps in an adjuvant setting. In first-line [treatment of] lung cancer, which is obviously the biggest market, 70 percent of patients are [eligible for] Keytruda plus chemo, and it’ll be more later. My expectation is that Keytruda will be foundational in the treatment of the majority of malignancies, and the question will be Keytruda plus what? It’s going to be Keytruda plus X, where X is going to be a large set of different things, and it will be much more personalized, depending on the tumor type. Dear god... he certainly seems to be zeroing in on DC Vax.